REQUEST PRICE

Fields with * are required
Premium Phosphosite-Specific 7TM Antibodies
Novel Tools for Your GPCR Research
Select Your Country of Delivery below

Immuno-Grade Dopamine Receptor 1 Antibodies

Close filters
No results were found for the filter!
Citations
KO-Validated
D1 (IHC-grade), Dopamine Receptor 1 Antibody
D1 (IHC-grade), Dopamine Receptor 1 Antibody
The D1 receptor antibody is directed against the distal part of the carboxyl-terminal tail of human D1. It can be used to detect total D1 receptors in Western blots independent of phosphorylation. The D1 antibody can also be used to...
$ 350.00

The dopamine D1 receptor belongs to the D1-like subfamily of dopamine receptors. It stimulates cAMP production by coupling to stimulatory G proteins. The classical view of dopamine receptor signaling implies that the D1 receptor stimulates the cAMP/PKA/DARPP-32 pathway. Moreover, D1 receptor-mediated PKA activation also results in the activation of the extracellular signal-regulated kinases 1/2 (Erk1/2) by two mechanisms: src-Shp2-dependent Erk1/2 phosphorylation and DARPP-32-mediated inhibition of protein phosphatase-1. It is believed that upregulation of these mechanisms, leading to aberrant Erk1/2 activation, are involved in the development of L-DOPA-induced dyskinesias in animal models of Parkinson’s disease.

The dopamine D1 receptor belongs to the D1-like subfamily of dopamine receptors. It stimulates cAMP production by coupling to stimulatory G proteins. The classical view of dopamine receptor... read more »
Close window
Immuno-Grade Dopamine Receptor 1 Antibodies

The dopamine D1 receptor belongs to the D1-like subfamily of dopamine receptors. It stimulates cAMP production by coupling to stimulatory G proteins. The classical view of dopamine receptor signaling implies that the D1 receptor stimulates the cAMP/PKA/DARPP-32 pathway. Moreover, D1 receptor-mediated PKA activation also results in the activation of the extracellular signal-regulated kinases 1/2 (Erk1/2) by two mechanisms: src-Shp2-dependent Erk1/2 phosphorylation and DARPP-32-mediated inhibition of protein phosphatase-1. It is believed that upregulation of these mechanisms, leading to aberrant Erk1/2 activation, are involved in the development of L-DOPA-induced dyskinesias in animal models of Parkinson’s disease.

Recently viewed